Cervical Intraepithelial Neoplasia (CIN) is an important premalignant disease risk for young women. AnGes MG and Tella, a Tokyo-based vaccine company, have announced to jointly develop a therapeutic vaccine for this indication.

AnGes MG press release, July 30, 2013